Hepatitis C (HCV) is currently the most prevalent life threatening disease among injection drug users, and complications from chronic HCV infection are likely to increase dramatically in this population in the next several years. Drug treatment programs are uniquely situated to provide critical HCV services to both IDUs and non-injecting drug users. Currently, however, there is virtually no systematic information about the drug treatment field's response to the HCV epidemic. The main purposes of the research are, therefore, to: (1) measure the extent to which three types of HCV services (education and counseling, antibody testing, and medical management and monitoring) are provided by a nationwide sample (N=800) of drug treatment programs, and compare the level of HCV related services across drug treatment modalities; (2) model the level of HCV services that these drug treatment programs provide on the basis of client characteristics, organizational structure and resources, relationships with public health organizations in the programs' environment, internal support for medical services, and the provision of other medical services (especially services for HIV and hepatitis A and B); (3) conduct case studies (N=24) of drug treatment programs in order to understand the innovation process (i.e., the adoption and development of HCV services) and the current implementation process (HCV service delivery practices and procedures); and (4) understand clients' perceptions of HCV services and the service delivery process in the case study sites, and whether their perceptions are congruent with those of staff. The research will analyze quantitative survey data to assess the structure of HCV services, and qualitative case study data to assess the innovation and implementation processes. The dissemination of research findings to the drug treatment field is expected to elevate consciousness about the need to properly respond to the HCV epidemic, assist advocates for HCV services in fostering the development of services, and assist programs that want to enhance services by informing them about """"""""best practices.""""""""

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
3R01DA013409-03S1
Application #
6613703
Study Section
Human Development Research Subcommittee (NIDA)
Program Officer
Flanzer, Jerry
Project Start
2000-08-01
Project End
2004-06-30
Budget Start
2002-07-01
Budget End
2003-06-30
Support Year
3
Fiscal Year
2002
Total Cost
$104,667
Indirect Cost
Name
National Development & Research Institutes
Department
Type
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10010
Strauss, Shiela M; Munoz-Plaza, Corrine; Rosedale, Mary T et al. (2011) Enhancing Drug Treatment Program Staff's Self-Efficacy to Support Patients' HCV Needs. J Soc Work Pract Addict 11:254-269
Strauss, Shiela M; Mino, Milton (2011) Addressing the HIV-related needs of substance misusers in New York State: the benefits and barriers to implementing a ""one-stop shopping"" model. Subst Use Misuse 46:171-80
Cohen-Moreno, Rinat; Schiff, Miriam; Levitt, Shabtay et al. (2010) Knowledge about Hepatitis-C among methadone maintenance treatment patients in Israel. Subst Use Misuse 45:58-76
Munoz-Plaza, Corrine E; Strauss, Shiela; Astone-Twerell, Janetta et al. (2008) Exploring drug users'attitudes and decisions regarding hepatitis C (HCV) treatment in the U.S. Int J Drug Policy 19:71-8
Strauss, Shiela M; Astone-Twerell, Janetta M; Munoz-Plaza, Corrine et al. (2007) Correlates of drug treatment program staff's self efficacy to support their clients'hepatitis C virus (HCV) related needs. Am J Drug Alcohol Abuse 33:245-51
Strauss, Shiela M; Astone-Twerell, Janetta; Munoz-Plaza, Corrine E et al. (2007) Drug treatment program patients'hepatitis C virus (HCV) education needs and their use of available HCV education services. BMC Health Serv Res 7:39
Strauss, Shiela M; Astone-Twerell, Janetta M; Munoz-Plaza, Corrine et al. (2006) Hepatitis C knowledge among staff in U.S. drug treatment programs. J Drug Educ 36:141-58
Strauss, Shiela M; Rindskopf, David M; Astone-Twerell, Janetta M et al. (2006) Using latent class analysis to identify patterns of hepatitis C service provision in drug-free treatment programs in the U.S. Drug Alcohol Depend 83:15-24
Strauss, Shiela M; Astone, Janetta M; Munoz-Plaza, Corrine et al. (2005) Residential substance user treatment programs as venues for HCV pharmacological treatment: client and staff perspectives. Subst Use Misuse 40:1811-29
Hagan, Holly; Strauss, Shiela M; Astone, Janetta M et al. (2005) Medical examinations at entry to treatment for drug abuse as an opportunity to initiate care for hepatitis C virus infection. Clin Infect Dis 40 Suppl 5:S297-303

Showing the most recent 10 out of 20 publications